AC Immune SA is a global leader in the development of precision medicine for neurodegenerative diseases, including Alzheimer's and Parkinson's. With cutting-edge technology platforms, AC Immune is at the forefront of pioneering precision medicine for neurodegeneration. Their mission is to preserve neurons and prevent disease through early and safe intervention.

AC Immune offers a range of products and services to achieve their goal. Their technology platforms, Morphomer® and Supraantigen®, deliver best-in-class small molecules and biologics. These platforms enable the monitoring of patients' specific proteinopathies, allowing for the well-timed selection of the most appropriate therapeutics.

AC Immune is also actively engaged in therapeutic vaccine strategies to prevent Alzheimer's and Parkinson's disease. As a company, AC Immune has a strong focus on scientific research and development. They have an impressive pipeline of potential treatments and therapies, with a therapeutic focus on neurodegenerative diseases.

AC Immune's dedication to precision medicine, backed by their innovative technology platforms, positions them as a leading player in the fight against neurodegenerative diseases